Moffitt logo

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Clinical Trials Search

Clinical Trial 20520

Cancer Type: Immunotherapy
Study Type: Treatment
NCT#: NCT03319940

Phase: Phase I
Prinicipal Investigator: Alberto Chiappori

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

Summary

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 monotherapy, in combination with anti-PD1 therapy and with additional cytokine release syndrome (CRS) mitigation strategies. AMG 757 will be administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Objective

Primary: For adult subjects with RR SCLC who progressed or recurred following platinum-based chemotherapy (Indication A) and ED SCLC with ongoing clinical benefit following no more than 6 cycles of platinum-based chemotherapy (Indication B): -Evaluate the safety and tolerability of AMG 757 -Determine the MTD or TP2D of AMG 757 Secondary: For Indications A and B: -Characterize the pharmacokinetics of AMG 757 -Evaluate preliminary anti-tumor activity of AMG 757 Exploratory: For Indications A and B: -Evaluate immunogenicity of AMG 757 -Evaluate protein, nucleic acid and cellular biomarkers in blood pre- and post AMG 757 treatment (eg cytokines, lymphocyte status, CTCs, sDLL3) -Evaluate relationship of baseline target protein expression in tumor tissue, tumor microenvironment characteristics and clinical benefit For Indication B only: -Evaluate the effects of chemotherapy and time elapsed post chemotherapy on "T cell fitness"

Treatments

Therapies

Medications

AMG 757 (); Pembrolizumab (Keytruda)

Inclusion Criteria

  • Subject has provided informed consent prior to initiation of any study-specific activities/procedures
  • Age greater than or equal to 18 years old at the time of signing the informed consent
  • Histologically or cytologically confirmed Small Cell Lung Cancer (SCLC):
  • Part A and Part C: RR SCLC who progressed or recurred following platinum-based regimen;
  • Part B: ED SCLC with ongoing clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) following no more than 6 cycles of first-line platinum-based chemotherapy with the last dose of chemotherapy greater than or equal to 28 days prior to the study day 1 (first-line consolidation setting)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Subjects with treated brain metastases are eligible provided they meet defined criteria
  • Adequate organ function as defined in protocol

  • Exclusion Criteria

  • History of other malignancy within the past 2 years prior to first dose of AMG 757 with exceptions
  • Major surgery within 28 days of first dose AMG 757
  • Untreated or symptomatic brain metastases and leptomeningeal disease Prior anti-cancer therapy: at least 28 days must have elapsed between any prior anti-cancer therapy and first dose of AMG 757
  • Exceptions:
  • Subjects who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to > Grade less than or equal to 1
  • Prior palliative radiotherapy must have been completed at least 7 days before the first dose of AMG 757
  • Subjects who experienced severe, life-threatening or recurrent (Grade 2 or higher) immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immune-oncology agents.
  • Has evidence of interstitial lung disease or active, non-infectious pneumonitis
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of AMG 757
  • Part C only: history of solid organ transplantation or active autoimmune disease that has required systemic treatment within the past 2 years

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    ;